Biologics

Orthobiologics company Bioventus is hoping to secure $100 million for its proposed stock offering, according to WRAL Tech Wire.

Richmond-based OrthoVirginia's Adam Crowl, MD, performed the first spinal fusion in clinic with the ViBone Moldable cell bone matrix, according to a Jan. 12 news release.

Peter Fields, MD, director of OrthoRegen in Santa Monica, Calif., is offering a stem cell therapy that combines four regenerative orthopedic procedures.

The global spinal biologics industry is projected to reach $2.3 billion by 2027, growing at a compound annual growth rate of 2.8 percent, according to ReportLinker.com.

Capital market company KICVentures Group has completed the acquisition of NanoFuse Biologics.

Health Canada has approved Zolgensma for the treatment of pediatric spinal muscular atrophy patients with three or less copies of the SMN2 gene, or infantile-onset SMA.

Eric Tobin has been announced as CEO of N2 Biomedical, a company providing coating and surface treatment for medical devices, according to a Dec. 2 press release.

A landmark clinical trial was announced in November when a $9 million grant was provided for the first human study using stem cells to treat a spinal disorder that occurs in babies in the womb.

Voters approved a proposition to provide $5.5 billion for stem cell research by the California Institute of Regenerative Medicine, according to a Nov. 13 press release.

The first human clinical trial using stem cells to treat spina bifida has been made possible thanks to a $9 million grant provided Nov. 12 by the California Institute for Regenerative Medicine.